This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • NGR006 A phase II study of NGR-hTNF administered a...
Clinical trial

NGR006 A phase II study of NGR-hTNF administered as single agent every 3 weeks in patients affected by colorectal cancer CRC , previously treated with fluoropyrimidine, oxaliplatin and irinotecan based regimens.

Read time: 1 mins
Last updated:24th Jan 2007
Antitumour activity defined as Progression Free Survival.
Category Value
Study start date 2007-01-24

View full details